Mabylon AG
PrivateLast Round
VC Round
Aug 12, 2025
Total Funding Raised
$1.48M
Company Overview
Mabylon AG operates in Healthcare & Life Sciences and is based in Schlieren. Its latest recorded funding round was a VC Round in August 2025.
Mabylon AG is a biotechnology company that discovers and develops human-derived antibody therapeutics for the treatment of allergies, inflammation, and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mabylon AG Comparables
Compare Mabylon AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IgGenix | 85% | |
| Dualitas Therapeutics | 78% | |
| Poplar Therapeutics | 77% |
For institutional investors. Book with your work email.
Mabylon AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Aug 12, 2025 | ||||
| Grant | Sep 24, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Mabylon AG Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The ALS Association | Grant |
| NIH RADx | Grant |
| Eurostars SME programme | Grant |
| Target ALS | Grant |
| Innosuisse | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 11, 2026
Monthly visitors increased 151% MoM.
- Apr 21, 2026
Monthly visitors grew 217% MoM, reaching 606.
For institutional investors. Book with your work email.
Mabylon AG Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mabylon AG's valuation, stock price, and market status.
Is Mabylon AG a public or private company?
Mabylon AG is a private company.
What is the current stock price of Mabylon AG?
Mabylon AG is a private company, so its shares have no public market price. Caplight tracks Mabylon AG's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mabylon AG worth (valuation)?
Valuation information for Mabylon AG is not publicly available.
Can I buy Mabylon AG stock?
Mabylon AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mabylon AG's last funding round?
Mabylon AG's most recent funding round was VC Round on August 12, 2025.
Who are the main investors in Mabylon AG?
Key investors in Mabylon AG include The ALS Association, NIH RADx, Eurostars SME programme, Target ALS, Innosuisse.
Will Mabylon AG IPO soon?
No public IPO plans have been announced for Mabylon AG.
How can I track Mabylon AG secondary market activity?
Caplight tracks bids, offers, and trades in Mabylon AG's shares on secondary markets.